Outlook Therapeutics (OTLK)
Develops and commercializes ophthalmic bevacizumab for wet age-related macular degeneration.
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industries Deep expertise spans commercial operations, capital markets, public company finance, and building scalable financial and operational infrastructure
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp
Outlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net revenues and a ramp tied to reimbursement.
Oncobiologics Q3 Earnings Call Highlights
Oncobiologics (NASDAQ: OTLK) said it is preparing for the U.S. commercial launch of LYTENAVA after the Food and Drug Administration approved the product as the only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration, or wet AMD, in the United States. President and Chief Executive Officer Bob Jahr called the approval
Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN)
enGene (NASDAQ: ENGN - Get Free Report) and Oncobiologics (NASDAQ: OTLK - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Insider and Institutional Ownership 64.2% of enGene shares are
Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript
Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript
Oncobiologics Q3 Earnings Call Highlights
Oncobiologics NASDAQ: OTLK said it is preparing for the U.S. commercial launch of LYTENAVA after the Food and Drug Administration approved the product as the only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration, or wet AMD, in the United States.
Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
Outlook Therapeutics, Inc. (OTLK) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.44 per share a year ago.
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
The only FDA-approved ophthalmic bevacizumab, LYTENAVA TM , addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used
Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Outlook Therapeutics, Inc. (NASDAQ:OTLK) will release its third quarter earnings report before the opening bell on Friday, Aug. 14.
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying warrants to purchase up to an aggregate of 55,555,556 shares of its common stock. The combined public offering price of each share of common stock and accompanying warrant to purchase one share is $0.99. The accompanying warrants have an exercise price of $1.10 per share, will become exercisable immediately and will expire five years from the date of issuance. Outlook Therapeutics also granted the underwriters an option for a period of 30 days to purchase up to 8,333,333 additional shares of its common stock and/or warrants to purchase up to 8,333,333 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the securities in the offering are to be sold by Outlook Therapeutics. The offering is expected to close on August 14, 2026 subject to market and other conditions.
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it has commenced an underwritten public offering of its common stock and accompanying warrants to purchase shares of its common stock. Outlook Therapeutics also intends to grant the underwriters a 30-day option to purchase additional shares of its common stock and/or accompanying warrants in an amount up to fifteen percent (15%) of the shares of its common stock and/or accompanying warrants offered in the public offering under the same terms and conditions. All of the securities in the proposed offering are to be sold by Outlook Therapeutics. The proposed offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Reviewing Oncobiologics (NASDAQ:OTLK) and Pasithea Therapeutics (NASDAQ:KTTA)
Oncobiologics (NASDAQ: OTLK - Get Free Report) and Pasithea Therapeutics (NASDAQ: KTTA - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability. Earnings and Valuation This table compares Oncobiologics and
OTLK Up More Than 300% in 3 Months: Here's What You Should Know
Outlook Therapeutics rallies 311.8% in three months as Lytenava's FDA approval boosts optimism ahead of its planned U.S. launch by year-end.
Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Outlook Therapeutics, Inc. (OTLK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
ISELIN, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it will report its financial results for the third quarter fiscal year 2026 and will host a corporate update conference call and webcast on Friday, August 14, 2026, at 8:30 AM ET.
Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?
OTLK heads into Q3 results with investors watching European Lytenava sales, U.S. launch plans and updates after its landmark FDA approval.
Outlook: 'Hold' - Caution On LYTENAVA FDA Approval And Cash Needs
Outlook Therapeutics (OTLK) receives both FDA and European approval for LYTENAVA, targeting wet AMD, but faces significant commercialization challenges. I downgrade OTLK to 'Hold' due to acute cash constraints and the urgent need for strategic funding or a partnership to support U.S. launch. LYTENAVA offers a lower-cost, ophthalmic bevacizumab alternative in a competitive $8.5B U.S. anti-VEGF retina market, but market capture remains uncertain.
US FDA approves Outlook Therapeutics' eye disease drug
Outlook Therapeutics said on Friday the U.S. Food and Drug Administration has approved its drug for a type of eye disease that can cause severe vision loss.
OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review
Outlook Therapeutics stock surges 35% after the FDA accepts the resubmitted Lytenava BLA for wet AMD for review, setting a July 29, 2026, decision date.
Outlook Therapeutics Eye Drug Review Returns To FDA For Fourth Time
Outlook Therapeutics Inc. (NASDAQ:OTLK) shares are rising in Wednesday premarket trading after the company announced the FDA accepted its resubmitted Biologics License Application (BLA) for ONS-5010/LYTENAVA.